Alcohol, tobacco and cannabis use among Spanish students aged 14–18 hits historic lows

Feb.09
Alcohol, tobacco and cannabis use among Spanish students aged 14–18 hits historic lows
Spain’s 2025 Survey on Drug Use in Secondary Education (ESTUDES), presented by the Ministry of Health, reports historic lows in alcohol, tobacco and cannabis consumption among students aged 14 to 18. The survey shows past-30-day drinking fell from 56.6% in 2023 to 51% in 2025, tobacco use from 21.0% to 15.5%, and cannabis use from 15.5% to 11.6%.

 

Key Takeaways

 

  • Survey: ESTUDES 2025, tracking adolescent drug use in Spain since 1994
  • Past 30 days (2025 vs 2023): alcohol 51% vs 56.6%; tobacco 15.5% vs 21.0%; cannabis 11.6% vs 15.5%
  • Binge drinking: 24.7%, cited as the lowest since measurement began
  • E-cigarettes: past-30-day use 27.1% vs 26.3%; past-year and lifetime measures down versus 2023
  • Sample: 35,256 students across 1,658 classrooms and 836 schools

 

 


 

 

 

2Firsts, Feb 9 2026

 

According to MundoAmerica, Spain’s Ministry of Health presented results from the 2025 Survey on Drug Use in Secondary Education (ESTUDES), reporting historic lows in alcohol, tobacco and cannabis consumption among students aged 14 to 18. The survey has tracked adolescent habits and drug use since 1994.

 

The report says Health Minister Mónica García and the Government Delegate of the National Drug Plan Xisca Sureda stated that in 2025, consumption of all psychoactive substances analysed has decreased or stabilised. García said “the new generations are changing and building a new way of understanding leisure and health.”

 

Based on the figures cited, past-30-day alcohol use fell from 56.6% (2023) to 51% (2025). Past-30-day tobacco use fell from 21.0% to 15.5%, described as the lowest figure recorded. Past-30-day cannabis use fell from 15.5% to 11.6%.

 

The report also says that compared with 1998, past-30-day alcohol consumption is 17 percentage points lower, tobacco is down more than 15 points, and cannabis is nearly 14 points below its historical peak in 2004. Binge drinking declined to 24.7%, which García described as “the lowest value since this type of consumption has been measured,” and she said the survey also shows an increase in perceived risks associated with drugs.

 

On e-cigarettes, Sureda was quoted as noting a slight increase in past-30-day use to 27.1% in 2025 from 26.3% in 2023, while measures of past-year and lifetime use declined compared with the previous survey.

 

The report says the 2025 survey involved 35,256 students from 1,658 classrooms and 836 centres across Spain.

 

Alcohol remains the most consumed legal drug among young people, the report says. It cites ESTUDES figures showing 73.9% of students reported lifetime alcohol use (vs 75.9% in 2023), 71.0% reported use in the past 12 months (vs 73.6%), and 51.8% reported use in the past 30 days (vs 56.6%). The average age of initiation remains 13.9 years, while weekly use and first drunkenness are reported at 14.8 and 14.6 years. García said that despite the historic lows, the figures “remain concerning,” and she and Sureda said it is “essential” for the Alcohol and Minors Law, expected to reach Congress soon, to move forward.

 

Tobacco use continues to decline, the report says. It cites figures of 27.3% lifetime smoking (vs 33.4% in 2023), 21.2% past-12-month use (vs 27.7%), and 15.5% past-30-day use (vs 21.0%). Daily smoking in the past month fell to 4.3%, down 3.2 percentage points from 7.5% in 2023. The average initiation age is 14.1 years, and starting daily smoking is 14.4 years. The report adds that the most common form combines packet cigarettes and roll-ups, and 46.4% of smokers attempted to quit in the past year.

 

Cannabis recorded one of the most significant decreases, Sureda said, according to the report. While it remains the most prevalent illegal substance, use declined across all timeframes: 21.0% lifetime (vs 26.9%), 15.5% past 12 months (vs 21.8%), and 11.6% past 30 days (vs 15.6%). The average age of initiation is 14.8 years, a tenth lower than the previous edition.

 

The report also cites a decline in lifetime use of hypnotics (tranquilizers and sleeping pills, with or without prescription) to 17.9%, described as the first decrease since 2014, with an average initiation age of 14 years. It adds that lower-prevalence substances such as hallucinogens, amphetamines, cocaine, heroin, MDMA and volatile inhalants also declined, including lifetime cocaine use down to 1.6% (vs 2.6% in 2023), hallucinogens at 1.4%, and volatile inhalants at 2.0%.

 

On risk perception, the report cites that perceived risk from habitual cannabis use reached the highest value in the ESTUDES series (94.1%). It also cites perceived risk of excessive weekend drinking at 67.6%, daily alcohol use at 66.2%, and that 93.3% of students believe daily smoking poses a high health risk.

 

Sureda said the historic low levels reflect a continued downward trend also seen in other European countries, the report says, attributing the decrease to prevention laws and interventions. García said “policies work” and that the government will continue working to create smoke- and alcohol-free environments.

 

Image Source: MundoAmerica

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
The U.S. FDA authorized 24 VELO nicotine pouch products from a British American Tobacco subsidiary, raising the total number of authorized products from 43 to 67, a 55.8% increase. The newly authorized 4 mg products include lime and passion fruit flavors and feature certified child-resistant packaging. VELO's first FDA marketing authorization adds BAT to a list previously limited to PMI and Altria products, while bringing the agency's nicotine pouch review pilot total to 47 authorized products.
Oct.30
Special Report | From Oversupply to Supply Gaps: Global Tobacco Leaf Markets Diverge Ahead of 2027
Special Report | From Oversupply to Supply Gaps: Global Tobacco Leaf Markets Diverge Ahead of 2027
Global tobacco leaf markets diverged sharply in 2026, with India cutting authorised FCV production amid oversupply while Malawi faced a supply shortfall. U.S. demand improved in some leaf categories, but growers in Brazil, Colombia, Tanzania and Zimbabwe faced pressure from prices, buyer access, costs and weather. With nicotine consumption patterns also shifting, 2027 will test whether supply, demand and grower profitability can move back toward balance.
Oct.26
Huabao International Buys Indonesian HNB Manufacturer for RMB 90 Million, Adding OEM/ODM Capacity
Huabao International Buys Indonesian HNB Manufacturer for RMB 90 Million, Adding OEM/ODM Capacity
Huabao International Holdings Limited will acquire 100% of PT Broad Far Indonesia through two wholly owned subsidiaries for approximately RMB 90 million. The Indonesian company manufactures and sells heat-not-burn tobacco sticks and provides OEM/ODM services. The sellers are part of a related-party group controlled by Huabao International Chair and controlling shareholder Zhu Linyao. PT Broad Far Indonesia generated $4.37 million in revenue and $177,000 in profit after tax in the first half of 2026, while net assets stood at about $326,000 at June-end. An independent valuer assessed the company’s equity at approximately RMB 93.06 million. Following completion, the HNB manufacturing operation will be consolidated into Huabao International.
News
Sep.29 by 2Firsts Perspectives
How Investors Are Repricing the Global Tobacco Industry as Nicotine Markets Shift
How Investors Are Repricing the Global Tobacco Industry as Nicotine Markets Shift
How are investors reassessing the global tobacco industry as nicotine markets evolve? In an interview with 2Firsts, Charlie Chen, Head of Research at CCB International Securities, forecasts annual growth of 30–50% for nicotine pouches, outpacing vaping and heated tobacco. He examines how regulatory enforcement, shifting market shares and new business models are influencing company valuations. The report also explores differences between multinational tobacco groups and Chinese companies, drawing on insights from the New Approaches Summit on profitability, investment strategies and industry consolidation.
Nov.11
Pennsylvania Lists 163 Vape Products Eligible for Sale, Including Vuse and JUUL; Previously Pending Chinese Brands Such as OXBAR Remain Absent, While Unlisted Products Including Geek Bar Face Enforcement From October 19
Pennsylvania Lists 163 Vape Products Eligible for Sale, Including Vuse and JUUL; Previously Pending Chinese Brands Such as OXBAR Remain Absent, While Unlisted Products Including Geek Bar Face Enforcement From October 19
Pennsylvania begins enforcing its electronic nicotine delivery system (ENDS) directory restrictions on October 19, 2026. The October 18 directory contained 163 product records from seven manufacturers, including Vuse, JUUL, NJOY, Logic and Naked 100. Geek Bar, RAZ and Lost Mary were absent. BAT, Altria, Japan Tobacco and JUUL collectively accounted for 112 records, or 68.7%, while Imperial Brands' blu had no listings. The directory included 15 disposable vape records, 40 bottled e-liquids and 10 products labeled 0mg, but no open-system refillable devices. Twenty-two manufacturer certifications remained under review. Four Logic models corresponding to Smoore's pending records were listed under the brand owner, while LYCO, OXBAR and Boulder/Rock had no approved directory entries.
Regulations
Oct.19
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives